Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
The company is moving ahead with Phase 3 plans for IPF-related chronic cough, supported by encouraging trial results and new funding. See our latest analysis for Trevi Therapeutics. After a remarkable year on the news front, Trevi Therapeutics has seen its share price climb an impressive 160.8% since January, while its total shareholder return tops 313% over the past twelve months. This rally reflects growing optimism around both clinical milestones and the recent boost in financial runway. Market momentum is clearly building as the company gears up for pivotal trials. If the pace of innovation in biotech has you looking for more discovery opportunities, it's a perfect moment to explore other healthcare names with market-moving potential: See the full list for free. With shares now trading well below most analyst price targets, even after such a strong run, is the market still underestimating Trevi's pipeline and cash runway? Or has all the good news already been priced in?
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial OfficerPR Newswire
- Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]Seeking Alpha
- How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 12/5/25 - Form 8-K
- 12/3/25 - Form 4
- 11/14/25 - Form SCHEDULE
- TRVI's page on the SEC website